AGENCY Healthcare Demand Generation
Book a Triage Call

Creative & Compliant Content › Medical Communications

Medical communications that drive demand, not just publications.

Traditional medical communications agencies run isolated publication programmes that look good in medical affairs reports and produce nothing for the commercial team. We do medical communications integrated with the rest of your launch and demand-generation programme: scientific narrative that supports the commercial story, KOL engagement that feeds your salesforce, peer-reviewed publications that survive formulary committee scrutiny, and HCP education that pulls clinicians toward your product. The clinical credibility is the same. The commercial impact is different.

Book a Triage CallSee our healthcare casework
Clinical reviewer and medical writer working through a scientific narrative draft at a congress

Does this sound familiar?

The Silo Problem

Your med comms agency produces beautiful publications. Nobody on the commercial team can use them. Sales has no idea a paper got accepted. Marketing finds out about KOL meetings after the fact. The work is good. The integration is non-existent.

The Launch Gap

You're 18 months out from launch. The clinical evidence is strong. The scientific platform is half-built. The commercial narrative isn't aligned to it. You need someone who can hold both the medical and commercial frames at once, before the launch window closes.

The KOL Drift

You've spent two years building relationships with twelve clinicians. They like the product. They're not advocating for it. The advisory boards are polite. The peer-to-peer activity isn't happening. The KOL programme has become a budget line, not a demand engine.

The Publication-to-Pipeline Gap

Your last three papers landed in respectable journals. Your sales team can't find them, can't translate them, and can't use them in a clinical conversation. The publications exist. The commercial value of them does not.

Medical communications has been treated as a silo for too long.

The traditional medical communications model puts publication planning, KOL engagement, and HCP education in a corner of medical affairs, sealed off from the commercial team. The argument is firewall and integrity. The result is medical-affairs activity that doesn't connect to anything else, and commercial activity that doesn't have the scientific credibility behind it.

We work differently. The clinical evidence still gets its rigour. The publications still go through peer review on their own merits. But the planning, the narrative architecture, and the KOL programme are built with the commercial team in the room, so the scientific story aligns to the product launch, the sales narrative, the patient marketing, and the formulary submission. Same firewall, same integrity, much more useful output.

We do not compete with the giant medical communications networks on scale. We compete on integration. If your launch needs medical communications that the rest of your launch machine can actually use, that's where we work.

A peer-reviewed paper nobody on the commercial team can find or use is half a deliverable.

How we deliver integrated medical communications.

Scientific narrative, publication planning, KOL engagement, HCP education. Built to flow into commercial, not sit beside it.

01

Scientific narrative architecture

First six weeks. We work with your medical and commercial leads to build the scientific narrative that holds your product's clinical story together: the evidence pyramid, the claims hierarchy, the differentiation against the standard of care, the publication targets. Output: a single document the medical, commercial, and access teams all reference for the next 24 months.

02

Publication planning & manuscript development

Manuscripts, abstracts, posters, supplements. Built against the scientific narrative, written by experienced medical writers with named clinical reviewers, targeted at journals where your HCP audience reads. Publication plan covers a rolling 12-18 months with milestones tied to commercial activity (launch, congress, formulary submission).

03

KOL & clinical champion programme

KOL identification mapped to your therapy area and commercial geography, not a generic clinical celebrity list. Engagement programme designed for peer-to-peer activity that actually moves your prescribers, including advisory boards, speaker programmes, congress sessions, and co-authored publications. Hand-off into your salesforce so reps know who their KOLs are and what's been agreed.

04

HCP education & scientific platform

Educational content for prescribers, payers, and the wider clinical community. Symposium content, congress activations, CME materials where the regulatory environment permits, scientific platform built once and re-used across channels. All MLR-cleared, all built to be picked up by the commercial team without re-versioning.

What you get from an engagement.

Scientific narrative document

The single source of truth for your product's clinical story. Evidence map, claims hierarchy, differentiation narrative, audience-specific versions for HCPs, payers, and patients. Updated quarterly.

Publication plan (12-18 month rolling)

Manuscript pipeline tied to commercial milestones. Target journals matched to audience reach. Authorship matrix agreed with KOLs upfront, not negotiated at submission.

Manuscripts, abstracts, posters

Medical writers with biomedical-science backgrounds, named clinical reviewers, full reference verification. Submission-ready packs including cover letters, response-to-reviewer templates, and disclosure paperwork.

KOL engagement programme

Mapped KOL list with engagement levels and history. Advisory board orchestration. Speaker programme management. Peer-to-peer activity tied to commercial geography. Quarterly KOL pulse for your commercial team.

HCP educational content

Symposium content, congress materials, scientific platform decks, prescriber-facing education. Built once, used across channels. MLR-cleared with version control.

Commercial hand-off pack

Every deliverable produced with a one-page commercial summary the sales team can actually use, plus a quarterly review with your sales and marketing leads to align on what's coming next.

Real medical communications. Real commercial integration.

Enterprise

Pharma launch, acute pain category

Problem

Pharma manufacturer launching an acute pain medicine in the UK. Strong clinical evidence, weak scientific narrative for the commercial story. KOL programme inherited from a prior agency was producing polite advisory boards and zero peer-to-peer activity. Sales team had no usable summary of any of the published evidence.

What we did

Rebuilt the scientific narrative around the commercial differentiation (length of stay, opioid escalation reduction, cost of pain pathway). Rationalised the KOL list against the commercial geography and reassigned engagement levels. Produced a commercial hand-off pack for every existing manuscript. Established quarterly KOL pulse with the sales team.

Result

Sales team reporting they finally had clinical evidence they could cite in a 90-second prescriber conversation. KOL meetings shifted from polite advisory to active co-authorship and speaker activity. Three new manuscripts in development, all aligned to commercial milestones.

Enterprise

Sermo, global physician community programme

Problem

Sermo runs the largest verified-physician community in the world. They needed scientific and educational content for an HCP audience at a cadence and quality their in-house team could not sustain, with the credibility their physician membership demands.

What we did

Built and delivered an ongoing programme of HCP-facing content with biomedical-science writers, clinician reviewers, and senior editors. 50+ articles to date, covering career, clinical, and educational topics, with the editorial rigour and physician-fluent voice the audience expects.

Result

Engagement metrics support Sermo's positioning as the go-to information resource for physicians. SEO and audience growth across the content areas covered.

Growing Companies

MedTech launch, HCP education at congress

Problem

MedTech company launching a new device with clinical evidence but no scientific platform for the major specialty congress eight weeks out. Booth was booked. Symposium slot was confirmed. No content existed for either.

What we did

Compressed scientific narrative build, symposium content design, congress activation plan, and KOL speaker briefing inside the eight-week window. Coordinated with the commercial team for booth integration so the congress investment worked as a single coherent activation.

Result

Symposium fully attended, congress booth lead capture above target, three peer-to-peer conversations with target KOLs that converted into post-congress engagement.

* A note on named work. Healthcare clients often need to keep brands, launches, and ongoing relationships private. We respect that. If the work above sounds like your situation, the triage call is the place to hear about similar engagements in confidence.

The economics your CFO needs to see.

A senior medical communications hire (medical writer or KOL liaison) costs GBP 75K to GBP 120K fully loaded. Most pharma and MedTech teams need both, plus a clinical reviewer panel, plus publication planning capability. Below GBP 500K of medical communications activity per year, building the full internal team is uneconomic. Above it, the math says hire and use a specialist agency for surge capacity and scientific narrative work.

Engagement pricing starts at GBP 8,500 per month for a focused programme (one manuscript pipeline, KOL pulse for one therapy area, one HCP educational track). Full integrated programmes for a launch run GBP 18,000 to GBP 35,000+ per month depending on publication volume, KOL programme scale, and HCP education breadth.

The CFO argument is the integration premium. A traditional med comms agency delivers a publication. We deliver a publication plus the commercial pack that lets your sales team use it. Same scientific output, materially more commercial utility, at comparable pricing.

Which situation are you in?

Pre-launch scientific platform build

You're 12-24 months out. The narrative isn't holding together yet.

Clinical evidence is strong, scientific narrative is fragmented, publication plan is reactive, KOLs are polite but not active. We build the integrated platform with you over a focused engagement. Launch readiness improves measurably inside the first quarter.

Launched but underperforming on HCP traction

Your published evidence isn't translating into prescriber behaviour.

Publications exist. KOL meetings happen. The sales team can't find or use any of it. We audit the existing programme, build the commercial hand-off layer, and rationalise the KOL list. Sales reports usable clinical content inside the first quarter.

Major congress or launch event approaching

Six to twelve weeks out and the scientific platform isn't ready.

Compressed engagement to build scientific narrative, congress activation content, symposium materials, and KOL speaker briefing inside the window. We've delivered launches on this timeline. Tight, expensive, possible.

By stage

What this looks like for your business.

Growing Companies

Pre-launch or early launch. You need scientific narrative architecture, a focused publication plan, and a KOL programme that's actually delivering peer-to-peer activity. Scope: scientific narrative document, 12-month publication plan, manuscripts and abstracts as needed, KOL programme for one therapy area, quarterly commercial review. From GBP 8,500 per month.

Enterprise

Full launch programme or multi-therapy-area portfolio. Scope: scientific narrative across multiple indications, rolling publication plan, named clinical reviewer panel, KOL programmes across geographies, congress and symposium activation, HCP educational content production, commercial hand-off integrated with sales and marketing. From GBP 18,000 to GBP 35,000+ per month.

Questions we hear in every triage call.

Are you a traditional medical communications agency?

No, and we say so deliberately. The traditional med comms model puts publications and KOL programmes in a sealed silo away from commercial. We do the same scientific and clinical work to the same standard, but we build it to integrate with launch, commercial, and demand-generation activity. If you need an isolated publication shop, we're not the right fit. If you need med comms that connects to the rest of your machine, that's where we sit.

How do you handle medical-affairs firewall and editorial independence?

The firewall stays intact on every deliverable that requires it (peer-reviewed manuscripts, regulatory-bound communications, scientific platforms). Editorial independence on publications is non-negotiable. The integration happens around the firewall, at the planning and hand-off layer, not inside the publication process itself. We have run this for pharma launches under strict MLR governance and the regulatory teams have been comfortable.

Do you have a named clinical reviewer panel?

Yes. For pharma and MedTech engagements requiring clinical sign-off, we attach named clinical reviewers to the account. Pre-clears scientific claims, validates evidence, signs off creative before MLR sees it. Materially reduces your in-house medical-affairs burden.

Can you work alongside our existing med comms agency?

Often. We've taken on the integration and commercial-utility layer for clients who keep their incumbent publication agency in place. The handoff is clean: incumbent owns the manuscript, we own the commercial pack, KOL coordination, and HCP educational re-use.

What therapy areas do you cover?

We work across pain, oncology, hospital-administered specialties, MedTech device categories, diagnostics, digital health, and patient-facing therapies. We do not pretend to specialise in every therapy area. For any engagement we name the medical writer and clinical reviewer with the relevant therapy-area depth upfront, and if we don't have the right specialist we'll say so.

How do you build the KOL list?

We map KOLs against three axes: clinical authority in the therapy area, geographic relevance to your commercial plan, and engagement track record (have they actually advocated, presented, published?). We rationalise inherited lists hard. Most KOL programmes carry 30-50% dead weight by the time we audit them.

What does the first 90 days look like?

Week 1-6: scientific narrative architecture built with medical and commercial leads. Week 7-10: publication plan agreed, KOL list rationalised, first manuscript and HCP education tracks underway. Week 11-13: first commercial hand-off pack delivered, quarterly KOL pulse established with your sales team. By day 90 you have the narrative, the plan, and the first commercial-utility output flowing.

Who delivers

Strategic Lead

Michael Colling-Tuck

20 years in healthcare commercialisation, 47 launches across 5 continents. Sits at the intersection of medical affairs and commercial. Owns the narrative architecture and the commercial hand-off integrity for every engagement.

Biomedical-science graduates

Medical Writers

Senior medical writers with biomedical-science backgrounds and significant healthcare publishing experience. Translate complex mechanism, evidence, and clinical guidelines into rigorous, peer-reviewed, and audience-appropriate output.

Named for pharma and MedTech

Clinical Reviewer Panel

Named clinicians attached to engagements requiring clinical sign-off. Pre-clear claims, validate references, sign off scientific creative. Cuts in-house medical-affairs review burden materially.

Mapped to therapy and geography

KOL Liaison

Senior medical communications experience in KOL identification, engagement design, and peer-to-peer activity orchestration. Maps the KOL programme to your commercial geography, not to a generic clinical celebrity list.

You might also need

Compliant Creativity Training

For teams running medical communications at scale. The SAFE framework keeps creative ambition and MLR reviewers on the same page from the first draft.

Learn more →

Medical Copywriting

If the work is content at HCP scale rather than peer-reviewed publication, the Medical Copywriting service is the better-fitting programme.

Learn more →

Sales Enablement

The commercial hand-off layer of medical communications connects directly to sales enablement. The EQUIP pillar of the 3 E's makes the published evidence usable on a clinical call.

Learn more →

Three ways to work with us.

The goal is always the same: you end up more capable, not more dependent.

Done by you

From GBP 850

Compliant Creativity training (SAFE framework) plus medical writing and scientific narrative workshops. Half or full day. We teach the methodology. Your in-house team runs it.

Book a workshop →

Done with you

From GBP 8,500/month

Focused medical communications programme: scientific narrative, one publication pipeline, one KOL therapy area, quarterly commercial reviews. Your team holds the relationships and the brand. We hold the production engine.

Start a programme →

Done for you

From GBP 18,000/month

Full integrated medical communications programme. Multi-indication scientific narrative, rolling publication plan, KOL programmes across geographies, HCP education, congress activations, full commercial hand-off integration.

Scale a programme →

Ready to talk?

30-minute triage call. No fee. No pitch. Bring your situation and we’ll tell you honestly whether we can help.

Book a Triage CallRead the Book

Healthcare innovations deserve recognition. We help them get it.